Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05546749 · ClinicalTrials.gov registry record · NA
Virtual Reality for Chronic Pain and Opioid Use Disorder Pilot
A NA study of Chronic Pain and Opioid Use Disorder, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05546749: Completed NA study of Chronic Pain and Opioid Use Disorder, sponsored by Albert Einstein College of Medicine.
NCT05546749 is a NA study of Chronic Pain and Opioid Use Disorder that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 18 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05546749, a NA study of Chronic Pain and Opioid Use Disorder, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot feasibility study of a virtual reality device for patients with co-morbid chronic pain and opioid use disorder.
Primary Outcome
Change in Pain Intensity from baseline was assessed using the single items Patient-Reported Outcomes Measurement Information System (PROMIS) pain intensity scale. Patients were asked to assess their average pain over the past 7 days on an 11-point Likert scale ranging from 0-10 where 0 = no pain and 10 = worst pain imaginable. Positive mean scores were associated with increased pain intensity from baseline and negative mean scores were associated with decreased pain intensity from baseline. Scor
Conditions Studied
Interventions
- DEVICE RelieVRx
- DEVICE Sham VR
Study Locations (1)
New York
- Melrose Clinic - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-02-08 |
| Est. Completion | 2023-07-12 |
| Phase | NA |
What the finished NCT05546749 record still lists
NCT05546749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which RelieVRx is the first listed.
NCT05546749 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05546749 about?
NCT05546749 is a clinical study titled "Virtual Reality for Chronic Pain and Opioid Use Disorder Pilot". This is a pilot feasibility study of a virtual reality device for patients with co-morbid chronic pain and opioid use disorder.
What is the current status of trial NCT05546749?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2023-02-08. Estimated completion is 2023-07-12.
What conditions does trial NCT05546749 study?
This clinical trial studies the following conditions: Chronic Pain, Opioid Use Disorder.
What interventions are being tested in trial NCT05546749?
The interventions under investigation include: RelieVRx (DEVICE), Sham VR (DEVICE).
Who is sponsoring clinical trial NCT05546749?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05546749 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05546749's enrollment target sits among peer trials
18 278th of 301 higher than 23 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Acceptability, Feasibility and Usability of Various Conversational Data Collection Software
RECRUITING · NA
-
Local Cerebral Oxygenation in Chronic Pain Patients Utilizing Spinal Cord Stimulation
RECRUITING · NA
-
Group Medical Visits and Chiropractic Care for Older Adults With Chronic Spine Pain
RECRUITING · NA
-
Emotional Awareness and Expression Therapy for People With Persistent Pain Following Orthopedic Trauma
RECRUITING · NA
-
Group-based Integrative Pain Management in Primary Care Safety Net Clinics
RECRUITING · NA
-
Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI